Transforming Cancer Therapies for Tomorrow

Pioneering Innovations in Oncology Treatment

Bharat Advanced Therapeutics (BAT) is a pioneering biotechnology company focused on developing New Chemical Entities (NCEs) to target cancers such as Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML). Our key molecules have been discovered by Prof. E Prem Kumar Reddy, Director of the Experimental Therapeutics Institute at Mount Sinai Hospital, New York City. With over $20 million invested in our pipeline, BAT is driving innovation to bring these therapies to patients in India, while our global development is spearheaded by AACT Inc. NYC.

Our Vision

We envision a future where transformative therapies for cancer are accessible, improving survival rates and the quality of life for patients worldwide. BAT strives to be at the forefront of oncology innovation, addressing some of the most challenging cancers.

Our Mission

Our mission is to deliver breakthrough cancer treatments by developing first-in-class oral small-molecule therapies. BAT is committed to advancing oncology care through innovative research, with a focus on providing safer, more effective treatments to patients with significant unmet medical needs.

Meet Our Talented Team

Our passionate and dedicated team brings together a diverse range of skills and expertise to deliver exceptional results. From creative visionaries to meticulous strategists, we work seamlessly together to meet and exceed our clients’ expectations.

Dr. Markandeya Gorantla
Founder

As the visionary behind BAT, Dr. Markandeya Gorantla leads the scientific strategy and development of innovative oncology therapies. His focus on addressing unmet needs in cancer has driven the development of BAT’s portfolio, including therapies for AML, CML, and other cancers.

Dr. Uday Saxena

Chair – PD and Director (BoD)

Dr. Uday Saxena is associated with the team that discovered Lipitor and Lopid, pioneering drugs in cholesterol and triglyceride treatment at Parke-Davis/ Pfizer. He has successfully taken multiple Investigational New Drugs (INDs) to the clinic and played a key role in licensing them to pharmaceutical giants. Under his leadership, BAT is advancing innovative cancer therapies, beginning with its lead drug candidate, BAT150030

Dr. Sree Voleti

COO

Dr. Sree Voleti oversees BAT’s day-to-day operations, bringing extensive experience in biotech operations, strategic planning, and project execution. His leadership ensures that BAT’s vision is translated into actionable strategies, supporting the company’s growth and development in oncology research.

Dr. Raghunadha Rao Digumarti

Chief of Clinical Trials

Dr. Raghunadha Rao is an eminent oncologist with over 40 years of experience in clinical oncology, specializing in trial design and execution. He has led numerous large-scale clinical trials and brings deep expertise in evaluating novel cancer treatments. As Chair of Clinical Trials at BAT, Dr. Rao oversees all clinical development programs, ensuring that BAT’s drug candidates are rigorously tested to meet global standards

Dr. Manmohan Acharya

Director, Clinical Trials

With a distinguished career in clinical oncology spanning over 20 years, Dr. Manmohan Acharya manages BAT’s clinical trial operations. He is responsible for the design, management, and execution of clinical studies, ensuring they are conducted with the highest standards of safety and efficacy.

Dr. V B Reddy Lachagari

Director, Genomics

Dr. Reddy leads the Genomics Division at BAT, bringing extensive expertise in genomic research and bioinformatics. He has a strong track record of applying genomic tools to cancer therapy development, enabling precision medicine approaches. Dr. Reddy plays a crucial role in integrating genomics into BAT’s drug development process, ensuring that our therapies are tailored to address the underlying genetic drivers of cancer, particularly in AML, CML, and other cancers in our pipeline.

Dr. Ramana Reddy

Scientific Director

With extensive expertise in drug discovery, Dr. Reddy focuses on identifying breakthrough therapeutic candidates for Acute Myeloid (AM) and Chronic Myeloid Leukemia (CML) cancers.
His visionary leadership and scientific rigor contribute significantly to developing next-generation solutions for advancing healthcare innovation. Dr. Reddy’s work exemplifies the seamless integration of scientific research and practical applications

Our Core Values

These principles guide our commitment to innovation, collaboration, and excellence in healthcare.

Integrity

We uphold honesty and transparency in all endeavors.

Innovation

We strive for groundbreaking solutions in cancer therapies.

Collaboration

We believe in teamwork to drive impactful results.

Compassion

We prioritize patient-centric care in our therapeutic approaches.

Join Us in Transforming Oncology Care

Discover how our advanced therapies can enhance lives. Connect with us today to learn more about our innovative solutions.

Learn More